Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 50

1.

Anticoagulation in heart failure: current status and future direction.

Gheorghiade M, Vaduganathan M, Fonarow GC, Greene SJ, Greenberg BH, Liu PP, Massie BM, Mehra MR, Metra M, Zannad F, Cleland JG, van Veldhuisen DJ, Shah AN, Butler J.

Heart Fail Rev. 2013 Nov;18(6):797-813. doi: 10.1007/s10741-012-9343-x. Review.

PMID:
22987320
2.

Novel oral anticoagulants in acute coronary syndrome.

Costopoulos C, Niespialowska-Steuden M, Kukreja N, Gorog DA.

Int J Cardiol. 2013 Sep 10;167(6):2449-55. doi: 10.1016/j.ijcard.2012.08.014. Epub 2012 Sep 16. Review.

PMID:
22989603
3.

The role of rivaroxaban in atrial fibrillation and acute coronary syndromes.

Reddy P, Giugliano RP.

J Cardiovasc Pharmacol Ther. 2014 Nov;19(6):526-32. doi: 10.1177/1074248414525505. Epub 2014 Mar 21. Review.

PMID:
24659084
4.

Preventing Thrombosis to Improve Outcomes in Heart Failure Patients.

Shantsila E, Lip GY.

Prog Cardiovasc Dis. 2016 Jan-Feb;58(4):386-92. doi: 10.1016/j.pcad.2015.09.005. Epub 2015 Oct 1. Review.

PMID:
26433062
5.

Novel oral anticoagulants for stroke prevention in atrial fibrillation: focus on apixaban.

Potpara TS, Polovina MM, Licina MM, Stojanovic RM, Prostran MS, Lip GY.

Adv Ther. 2012 Jun;29(6):491-507. doi: 10.1007/s12325-012-0026-8. Epub 2012 Jun 7. Review.

PMID:
22684583
6.

Non-vitamin K antagonist oral anticoagulants in cardiovascular disease management: evidence and unanswered questions.

Cheng JW, Barillari G.

J Clin Pharm Ther. 2014 Apr;39(2):118-35. doi: 10.1111/jcpt.12122. Epub 2014 Jan 3. Review.

PMID:
24383983
7.

Atrial fibrillation and heart failure: Factors influencing the choice of oral anticoagulant.

Brown LAE, Boos CJ.

Int J Cardiol. 2017 Jan 15;227:863-868. doi: 10.1016/j.ijcard.2016.09.086. Epub 2016 Sep 30. Review.

PMID:
28029411
8.

Combined anticoagulation and antiplatelet therapy for high-risk patients with atrial fibrillation: a systematic review.

Lane DA, Raichand S, Moore D, Connock M, Fry-Smith A, Fitzmaurice DA; Steering Committee.

Health Technol Assess. 2013 Jul;17(30):1-188. doi: 10.3310/hta17300. Review.

9.

Antiplatelet versus anticoagulation treatment for patients with heart failure in sinus rhythm.

Shantsila E, Lip GY.

Cochrane Database Syst Rev. 2016 Sep 15;9:CD003333. [Epub ahead of print] Review.

PMID:
27629776
10.

Thromboembolism and antithrombotic therapy for heart failure in sinus rhythm: an executive summary of a joint consensus document from the ESC Heart Failure Association and the ESC Working Group on Thrombosis.

Lip GY, Piotrponikowski P, Andreotti F, Anker SD, Filippatos G, Homma S, Morais J, Pullicino P, Rasmussen LH, MarĂ­n F, Lane DA; Heart Failure Association (EHFA) of the European Society of Cardiology (ESC) and the ESC Working Group on Thrombosis.

Thromb Haemost. 2012 Dec;108(6):1009-22. doi: 10.1160/TH12-08-0578. Epub 2012 Oct 23.

PMID:
23093044
11.

New oral anticoagulants in atrial fibrillation and acute coronary syndromes: ESC Working Group on Thrombosis-Task Force on Anticoagulants in Heart Disease position paper.

De Caterina R, Husted S, Wallentin L, Andreotti F, Arnesen H, Bachmann F, Baigent C, Huber K, Jespersen J, Kristensen SD, Lip GY, Morais J, Rasmussen LH, Siegbahn A, Verheugt FW, Weitz JI; Coordinating Committee.

J Am Coll Cardiol. 2012 Apr 17;59(16):1413-25. doi: 10.1016/j.jacc.2012.02.008. Review.

12.

Potential role of rivaroxaban in patients with acute coronary syndrome.

Fitchett DH.

Drug Des Devel Ther. 2012;6:349-57. doi: 10.2147/DDDT.S30342. Epub 2012 Nov 22. Review.

13.

Antiplatelet and anticoagulant agents in heart failure: current status and future perspectives.

Gurbel PA, Tantry US.

JACC Heart Fail. 2014 Feb;2(1):1-14. doi: 10.1016/j.jchf.2013.07.007. Epub 2014 Jan 8. Review.

PMID:
24622113
14.

Role of novel and emerging oral anticoagulants for secondary prevention of acute coronary syndromes.

Ganetsky VS, Hadley DE, Thomas TF.

Pharmacotherapy. 2014 Jun;34(6):590-604. doi: 10.1002/phar.1375. Epub 2013 Dec 13. Review.

PMID:
24338703
15.

New and emerging anticoagulant therapy for atrial fibrillation and acute coronary syndrome.

Davis EM, Packard KA, Knezevich JT, Campbell JA.

Pharmacotherapy. 2011 Oct;31(10):975-1016. doi: 10.1592/phco.31.10.975. Review.

PMID:
21950643
16.

Antiplatelet agents and anticoagulants for hypertension.

Lip GY, Felmeden DC, Dwivedi G.

Cochrane Database Syst Rev. 2011 Dec 7;(12):CD003186. doi: 10.1002/14651858.CD003186.pub3. Review.

PMID:
22161375
17.

Oral antithrombotic therapy in atrial fibrillation associated with acute or chronic coronary artery disease.

Cairns JA, McMurtry MS.

Can J Cardiol. 2013 Jul;29(7 Suppl):S60-70. doi: 10.1016/j.cjca.2013.04.006. Review.

PMID:
23790600
18.

New oral anticoagulants for atrial fibrillation: a review of clinical trials.

O'Dell KM, Igawa D, Hsin J.

Clin Ther. 2012 Apr;34(4):894-901. doi: 10.1016/j.clinthera.2012.01.019. Epub 2012 Mar 13. Review.

PMID:
22417716
19.

Rivaroxaban for stroke prevention in atrial fibrillation and secondary prevention in patients with a recent acute coronary syndrome.

Ahrens I, Bode C.

Future Cardiol. 2012 Jul;8(4):533-41. doi: 10.2217/fca.12.26. Review.

PMID:
22871192
20.

NOAC in acute coronary syndrome and AF?

Niespialowska-Steuden M, Collins P, Costopoulos C, Gorog DA.

Cardiovasc Hematol Disord Drug Targets. 2014;14(2):154-64. Review. Erratum in: Cardiovasc Hematol Disord Drug Targets. 2015;15(1):85.

PMID:
24993123

Supplemental Content

Support Center